化疗联合CIK免疫疗法治疗晚期消化道肿瘤86例观察  

Chemotherapy Combined with CIK Cells Immunotherapy in Treatment of 86 Patients with Advanced Digestive Malignant Tumor

作　　者：李霞[1] 赵稳兴[2] 蔡琳[2] 崔静[2] 王媛媛[2] 徐文漭[2] 

机构地区：[1]成都军区昆明总医院全军创伤骨科研究所,昆明650032 [2]成都军区昆明总医院病理科,昆明650032

出　　处：《解放军医药杂志》2014年第5期38-40,61,共4页Medical & Pharmaceutical Journal of Chinese People’s Liberation Army

基　　金：云南省应用基础研究自筹项目(2010ZC186)

摘　　要：目的：探讨化疗联合CIK免疫疗法对晚期消化道肿瘤的效果。方法采用化疗（方案以奥沙利铂、氟尿嘧啶、卡培他滨为主）联合CIK免疫疗法治疗2005年10月-2010年1月成都军区昆明总医院收治的晚期消化道恶性肿瘤86例（观察组）,将同期仅接受化疗的63例晚期消化道肿瘤设为对照组,分别于完成第2、4个疗程后2周检测两组相关免疫指标（ CD56＋、CD3＋、CD3＋CD56＋、CD3＋CD8＋T细胞）,完成第2个疗程后观察两组临床症状（体重减轻、消化道出血、恶心、呕吐）改善情况和总生存期,同时对比疗效。结果完成第2、4个疗程后观察组免疫指标均高于对照组（P〈0．05,P〈0．01）。完成第2个疗程后观察组体重减轻、消化道出血、恶心和呕吐症状均明显缓解（P〈0．05,P〈0．01）。两组近期疗效差异无统计学意义（P〉0．05）。患者均获随访,随访时间0.5~5年,观察组中位生存期28个月,对照组中位生存期9个月,log-rank检验两条生存曲线差异有统计学意义（χ2=4.851,P=0.028）。结论化疗联合CIK免疫疗法治疗晚期消化道肿瘤,能够提高患者的免疫功能、减轻临床症状、延长生存期。Objective To explore the effect of chemotherapy combined with CIK cells immunotherapy in treat-ment of advanced digestive malignant tumor. Methods A total of 86 patients with advanced gastrointestinal cancer （ ob-servation group） were treated with chemotherapy （ main components of Oxaliplatin, Fluorouracil, Capecitabine） com-bined with CIK immunotherapy during October 2005 and January 2010 in Kunming General Hospital, and 63 patients with advanced gastrointestinal tumors （ control group） received only chemotherapy at the same period. The related immune pa-rameters （ CD56 ＋, CD3 ＋, CD3 ＋CD56 ＋, CD3 ＋CD8 ＋ T cells） of the two groups were detected two weeks after 2 nd and 4th courses of treatment were finished respectively, and improvements of clinical symptoms （weight loss, gastrointestinal bleeding, nausea and vomiting） and total life span were observed, and clinical effect was synchronously compared after 2nd course of treatment was completed in the two groups. Results After 2nd and 4th course of treatment was completed, the immune parameters in observation group were higher than those in control group （P〈0. 05, P〈0. 01）. After 2nd course of treatment was completed, weight loss, gastrointestinal bleeding, nausea and vomiting were significantly allevia-ted in observation group （P〈0. 05, P〈0. 01）, and the difference in recent curative effect was not statistically signifi-cant （P〉0. 05）, and the difference in recent curative effect was not statistically significant （P〉0. 05） . All patients were followed up for 0. 5 - 5 years, the median life span in observation group was 28 months;median life span in control group was 9 months, and the difference in survival curves by log-rank test was statistically significant （χ2 =4. 851, P=0. 028）. Conclusion Chemotherapy combined with CIK cells immunotherapy in treatment of advanced digestive malig-nant tumor may improve immune function, relieve clinical symptoms and prolong life span.

关 键 词：消化系统肿瘤 免疫疗法 细胞因子诱导的杀伤细胞 抗肿瘤联合化疗方案 

分 类 号：R735[医药卫生—肿瘤] R392.12[医药卫生—临床医学]